Neuropathy associated with anti-GD1b ganglioside antibodies

Peripheral Neuropathies

Updated 05.28.2024
Released 12.22.1998
Expires For CME 05.28.2027

Neuropathy associated with anti-GD1b ganglioside antibodies

Authors: Mazen M Dimachkie MD, Bhaskar Roy MBBS MHS

See Contributor Disclosures

Editor: Louis H Weimer MD

Neuropathy associated with anti-GD1b ganglioside antibodies

In This Article

Quick Link

Introduction

Overview

Autoantibodies against GD1b, a ganglioside abundant in the nervous system, have been implicated in neuropathy for over three decades. However, the exact pathomechanism of these antibodies and the full spectrum of the clinical phenotype associated with these antibodies are not well defined. These antibodies alone, or in combination with other ganglioside antibodies, have been found with acute postinfectious neuropathy as well as in chronic neuropathy and can be associated with paraproteinemia. Sensory deficit, areflexia, and ataxia are commonly noted in neuropathies associated with GD1b antibodies. Although some patients do respond to intravenous immunoglobulin, rituximab can also help a subset of patients.

Key points

	• Anti-GD1b IgG antibodies are more frequently present in acute ataxic neuropathy syndrome, including a sensory ataxic variant of Guillain Barré syndrome
	• Anti-GD1b IgM antibodies are common in chronic neuropathy or chronic ataxic neuropathies with antidisialosyl ganglioside immunoglobulin M antibodies, and ataxia can be a prominent feature.
	• In comparison to the chronic ataxic neuropathy with disialosyl antibodies (CANDA) nomenclature, chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies (CANOMAD) additionally highlights ophthalmoplegia and cold agglutinins, but these clinical and laboratory features are not universally present.
	• Neuropathy associated with anti-GD1b antibody is usually responsive to immunoglobulin, but B cell depletion therapies, such as rituximab, can be helpful.

Historical note and terminology

In the early 1980s, there was a growing interest in peripheral neuropathy syndromes associated with paraproteinemia, a condition also referred to as monoclonal gammopathy. This condition is characterized by the presence of heavy or light chains of monoclonal immunoglobulin, or its fragments, in blood secondary to clonal proliferation of plasma cells of B cell lineage (54; 15). These paraproteins were frequently directed to carbohydrate determinants present on different glycoproteins and glycolipids distributed in neural tissue, and antibodies against myelin-associated glycoprotein and structurally related glucuronic acid-containing acidic glycosphingolipids were the first to be identified (05).

Gangliosides are a class of complex glycolipids composed of a ceramide attached to one or more sugars (hexoses) and contain sialic acid (N-acetylneuraminic acid) linked to an oligosaccharide core. They are abundant in peripheral nerves and participate in the maintenance and repair of neuronal cells, modulation of cell growth, memory formation, and synaptic transmission (78; 09). The number of sialic acid residues attached to the inner sugar moiety determines the classification of a ganglioside (M for one [mono], D for two [di], T for three [tri], and Q for four [quadri]). The numbering of the gangliosides is based on the number (x) of the inner sugar moieties (glucose, galactose, or GalNAc) with a formula of 5−x. If there are four sugar moieties (x=4), the gangliosides are GM1, GD1, and GT1; if x = 3, then GM2, GD2, and GT2; and for x=2, they are GM3, GD3, and GT3 (78; 09). In 1985, a case of IgM paraproteinemic neuropathy in which the paraprotein reacted with NeuNAc(alpha2-8) configured disialylated gangliosides, including GD1b, GD3, GD2, and GT1b was reported (26). Following this report, several other cases similarly characterized by chronic sensory ataxic neuropathy were reported in the early 1990s (02; 11; 47; 77; 80; 72; 20; 21). A series of 18 cases was reported in 2001 that better captured the clinical spectrum of the syndrome (71).

On the other hand, acute phase anti-GD1b IgG antibodies have been identified in isolated patients with acute sensory neuropathies, acute ataxic neuropathies, or both, without limb weakness, which is considered a forme fruste or regional variant of Guillain Barré syndrome (73; Yuki and Hirata, 1998; Willison and Yuki, 2002). Some patients with Miller-Fisher syndrome (MFS or Fisher syndrome) also have anti-GD1b antibodies by virtue of their cross-reactivity with anti-GQ1b/GT1a antibodies (07; 73; 62). Ataxia is more likely to be present in patients with highly specific IgG against GD1b (31).

Clinical manifestations

Presentation and course

	• Acute acquired neuropathies are usually associated with anti-GD1b IgG antibodies, and the clinical features can be variable.
	• Chronic ataxic neuropathy with disialosyl antibodies (CANDA) and chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies (CANOMAD), a subtype of CANDA, are associated with anti-GD1b IgM antibodies.
	• CANDA and CANOMAD are more common in men aged 30 to 81 years.
	• Motor involvement is not a typical feature but can be present.
	• CANDA and CANOMAD have been reported in the context of hematological malignancies.

Antibodies to GD1b/GD1a ganglioside complexes are present in a proportion of Guillain-Barré syndrome (32; 28). Several case reports have suggested the presence of ataxia in patients with Guillain-Barré syndrome and GD1b IgG antibody. Interestingly, both sensory ataxia and cerebellar ataxia have been reported (68; 03; 81; 22; 23; 50). Highly specific, GD1b IgG antibodies have been reported to be more likely to lead to sensory ataxia (31). However, the clinical features of GD1b-associated Guillain-Barré syndrome can extend to involve cranially innervated muscles and may even lead to ophthalmoplegia (04; 44; 01). Occasionally, the presence of GD1b IgG antibody has been reported in the Miller-Fisher syndrome variant, even in the absence of GQ1b antibody (18; 45; 13; 36). Usually, GD1b IgG antibody in Guillain-Barré syndrome is present along with other anti-ganglioside antibodies, but mono-specific presence of GD1b has been rarely reported (68; 79; 81; 31; Bhagat abd Brown 2021). However, overall, the frequency of anti-GD1b antibodies in Guillain-Barré syndrome is low, as it is present in approximately 11% to 12% cases of classic Guillain-Barré syndrome and 14.3% cases of Miller-Fisher syndrome (66). Anti-GD1b IgG-mediated neurologic symptoms related to COVID have been reported, but clinical phenotype has varied significantly, including cranial neuropathy with meningo-polyradiculitis and brainstem encephalitis (45; 18; 17; 16). There are rare reports of dysphagia following COVID-19 in association with Anti-GD1b IgM (34).

Similar to Guillain-Barré syndrome associated with GD1b IgG antibody, chronic sensory neuropathy associated with anti-GD1b IgM antibodies is a rare disorder, and the majority of the literature is based on case reports. IgM anti-GD1b is reported in about 2.4% cases of Guillain-Barré syndrome (versus 12.1 for IgG GD1b antibodies), 3% cases of monoclonal gammopathy of unknown significance neuropathy (compared to 52/101 MGUS patients with MAG antibody from the same series), and also in one patient with paraneoplastic anti-Hu associated neuropathy (64). To date, 181 cases have been reported with four case series reporting more than 10 patients (71; 14; 40; 51). Seventy-seven percent of reported cases were male, and the age range varied between 30 and 81 years. Disease onset is usually insidious or chronic, but acute presentation is reported in 18% to 22% of patients (71; 40; 51). Interestingly, in some cases, the initial presentation was acute and treatment-responsive, and the relapse or the second event happened years later (56). Several patterns of onset have been described in the chronic form of the illness: insidiously progressive, acute relapsing and remitting, and acute relapses on a chronic background, often extending for more than 10 years. In addition to the chronic syndrome, patients with craniobulbar motor involvement may have these either as a fixed set of symptoms or as relapsing-remitting symptoms. These comprise double vision and eyelid drooping, dysphagia, and dysarthria. The episodes of relapse affecting the craniobulbar motor system may be mistaken for brainstem strokes or central demyelination; however, it should be borne in mind that central nervous system manifestations may also be present in these chronic cases, which are yet to be fully defined (71; 40; 51).

The antidisialosyl IgM antibodies are usually associated with a clinical syndrome with chronic sensory ataxia without functionally substantial limb weakness in most cases. Large fiber sensory loss to vibration and proprioception is a common finding, and most patients also have sensory paresthesia (71; 14; 40; 51). Areflexia is usually present in more than 90% cases (40). Motor weakness is rare at the time of diagnosis but may present later in fewer than 30% to 40% cases. Both distal and proximal motor weakness have been reported (71; 14; 40; 51). In some cases, the IgM paraprotein also has cold agglutinating activity with anti-Pr specificity (02; 72; 20). In other cases, craniobulbar motor involvement, including ophthalmoplegia, may also be present (25; 20; 71). To reflect this, in 1996 the acronym CANOMAD was coined to encompass this phenotype: chronic ataxic neuropathy with ophthalmoplegia, M-protein, agglutination, and disialosyl antibodies (70). Although this acronym is useful, not all cases exhibit the full spectrum of clinical features. Considering the limitations of this acronym and potential restriction in terms of diagnosis, an alternative acronym, CANDA (chronic ataxic neuropathy with disialosyl antibodies), has been proposed (82). This acronym recognizes the strong association between ataxia and anti-GD1b antibodies (61).

In the initial case series by Willison and colleagues, all patients had at least cranial nerve 3 involvement, and ataxia was present in all but one patient (71). The clinical features of another series of 11 cases have been reported, adding to the consistent pattern of this presentation (14). In a Japanese series of five cases of sensory ataxic neuropathy with anti-GD1b antibodies and IgM paraproteinemia, all patients had severe sensory ataxia and areflexia, but only one of the five cases manifested a transient diplopia on lateral gaze, and two of the five cases had cold agglutinins (62). In contrast, two cases reported as part of a long-term follow-up of paraproteinemic neuropathy cases had all the features of CANOMAD (52). Two large series of CANOMAD/CANDA patients (at least one serum IgM antibody reacting against disialosyl epitopes among GD1b, GD3, GT1b, and GQ1b) from France and Switzerland confirmed previous findings and reported sensory ataxia in 76% to 85% of patients (40; 51). One case series from the United States reported tremor in more than 90% of cases and pseudoathetosis in 27% of cases (14).

Among other clinical symptoms, motor and sensory involvement of cranial nerves, particularly the fifth and seventh nerves, can be present (71; 40). Two cases have reported the concomitant presence of optic neuropathy (57). Unusual manifestations include choreoathetoid movements of the face and tongue and respiratory insufficiency requiring intubation (30). Some cases may have autonomic involvement with pupillary abnormalities and bladder or bowel symptoms; however, these are rarely symptomatically prominent (40).

Prognosis and complications

Typically, CANDA and CANOMAD are treatment-responsive with relapsing-remitting features. As mentioned before, relapse after many years of stability is not uncommon. In some cases, the disease can be progressive. Despite relative motor strength sparing, limb ataxia may lead to significant disability, and some patients are unable to walk without assistive devices. About 7% to 27% of patients become wheelchair-dependent (71; 14; 40; 51). Reports of bulbar dysfunction varied between less than 10% to 66% cases and, when present, can lead to swallowing-related complications, including impaired nutrition and aspiration (71; 14; 40; 51).

Clinical vignette

A 67-year-old woman was first noted by her local blood transfusion laboratory to have cold agglutinins when examined at 49 years of age. At 55 years of age, she presented with paraesthesia and numbness first affecting her feet and then her hands. She also had difficulty with fine finger movements and unsteadiness while walking, particularly in the dark. She was only able to walk with the aid of a walking frame. She later developed variable and intermittent symptoms of ptosis and double vision, alterations in the quality of her voice, and difficulty with chewing and swallowing, in addition to perioral paraesthesia. She did not have symptoms or signs of cold agglutinin disease.

On examination, she had an area of perioral sensory loss to pinprick, mild bilateral ptosis, impaired pupillary light responses, and otherwise normal cranial nerves. There was no wasting or weakness in the limbs. She was areflexic. Glove and stocking sensory loss to light touch and pinprick was present, with an additional area of sensory loss over the mid-abdominal region and sternum. Joint position sense was markedly impaired in the digits, and vibration sense was absent to the elbows and ribs. Deep pain and thermal sensation were normal. She had prominent pseudoathetosis of the outstretched hands and gait ataxia with a positive Romberg test. She was unable to walk unaided.

Electrophysiological examination of motor nerves revealed prolonged distal motor latencies and F wave latencies (right common peroneal distal motor latencies: 6.9 msec, F wave: 76.4 m/sec; right tibial distal motor latencies: 5.8 m/sec, F wave: 83.9 m/sec; right median distal motor latencies: 5.2 m/sec, F wave: 43.2 m/sec). Motor conduction velocities in the leg and arm were reduced (right common peroneal: 34 m/sec; right tibial: 30.5 m/sec; right median: 37.5 m/sec). All sensory nerve action potentials examined (right sural, median, ulnar, and radial) were absent. Needle electromyography revealed borderline neurogenic changes. Visual evoked potentials were normal. CSF examination was normal, with a protein level of 0.36 g/L.

Sural nerve biopsy demonstrated a severe reduction in large myelinated fibers with preservation of the unmyelinated small fiber population.

Sural nerve biopsy (electron microscopy)

There is a reduced density of myelinated fibers with relative preservation of unmyelinated fibers. Inflammatory cells are not seen. Bar = 5 microns. (Contributed by Dr. Hugh Willison.)

No active fiber degeneration or demyelination was observed, although there was a degree of axonal regeneration with some isolated fibers surrounded by thin myelin sheaths suggestive of remyelination. There were no hypertrophic changes, and no inflammatory cells or immunoglobulin deposits were noted.

Laboratory tests revealed a normal full blood count, elevated ESR at 96 mm/hr (recorded at room temperature), elevated serum IgM at 6.4 g/L with an IgM-lambda paraprotein at around 4.0 g/L and normal serum IgG and IgA levels. Bone marrow examination, urine analysis for Bence Jones proteinuria, and skeletal survey were normal. Examination of the patient’s serum by ELISA demonstrated IgM antibodies reactive with all gangliosides containing NeuNAc(a2-8)NeuNAc(a2-3) configured disialosyl groups at titers in excess of 1/105. The highest titers were, thus, obtained with GD1b (1/850,000), GQ1b (1/450,000), GT1b (1/300,000), and GD3 (1/260,000). Weak reaction was observed with GD1a (1/570) and GM3 (1/660), which contain a terminal NeuNAc(a2-3)Gal(b1-) structure. The monosialic series gangliosides GM1 and GM2 gave no reaction, neither did asialo-GM1.

Red blood cell studies on the serological reactions of her cold agglutinins demonstrated that they (1) were strongly agglutinated all "common phenotype" red blood cells, including cord cells, (2) did not agglutinate neuraminidase-treated human or canine red blood cells, (3) weakly agglutinated papain modified red blood cells, (4) weakly agglutinated MkMk red blood cells; (5) strongly agglutinated "common phenotype" red blood cells modified by mild treatment with sodium metaperiodate, and (6) strongly agglutinated canine red blood cells both before and after modification with papain. These characteristics are typical of anti-Pr2 specificity.

She was initially treated with a single course of plasma exchange (total exchange 15 liters) followed by low-dose oral cyclophosphamide (150 mg/week in three divided doses). She reported an improvement in her sensory symptoms, hand function, and mobility after 8 months of treatment, although there was no quantifiable evidence of this, and she remained significantly disabled. She was subsequently treated with 2 g/kg of intravenous human immunoglobulin, again with no definite improvement, either symptomatically or objectively.

Biological basis

Etiology and pathogenesis

Like many other autoimmune diseases, the exact pathophysiology of GD1b-mediated neuropathy remains unclear. However, there is experimental evidence to suggest a direct role of the anti-GD1b in disease pathophysiology. Sensitizations of six rabbits with GD1b led to the production of IgM anti-GD1b antibodies, with a low titer of antibody against GM1, but no cross-reactivity was noted against GD1a or GT1b. Three of six rabbits developed neurologic symptoms with splayed limbs and awkward functioning of the limbs and retained motor power. No definitive cranial nerve dysfunction was present, and no conduction block was detected. Positive immunostaining was noted in dorsal root ganglia but not in ventral roots and paranodal myelin. There was axonal degeneration with loss of cell bodies in dorsal root ganglia, but no demyelinating features or mononuclear cell infiltrations were observed (39). Dorsal root ganglion neurons might be injured by antibody-mediated downregulation of trkC, leading to growth factor deprivation and subsequent neuronal apoptosis (65).

GD1b has been shown to be present on dorsal root ganglion neurons; thus, anti-GD1b antibodies may bind at this site, which is relatively deficient in the blood-nerve barrier and can cause antibody and complement-mediated injury. In fact, whole serum from a patient with CANOMAD only bound to dorsal root ganglia but not to the sciatic nerve, lumbar spine, or paranodal area (48; 38). However, other reports suggested more widespread immunoreactivity of IgM cold agglutinating antibodies from patients with CANOMAD, including sensory and motor nerves, third cranial nerve, with prominent staining in groups of dorsal root ganglia neurons but sparing the myelin or paranodal area in both murine and human tissue (70; 29). Thus, the balance of the existing evidence points to a direct role for anti-GD1b antibodies in causing dorsal root ganglion neuronal injury, but this remains to be fully investigated mechanistically (10).

Motor nerve terminals in selected sites, such as in craniobulbar muscles, may also be affected by antibody binding similar to that which occurs in Miller-Fisher syndrome (55). In support of this, an immunohistological study has shown that anti-GD1b antibodies and related antibodies reactive with other disialylated gangliosides bind to motor end plates in human extraocular muscle (41). In contrast, binding to end plates in limb muscles was sparse, but the nerve terminals inside muscle spindles and in direct contact with intrafusal fibers were labeled with anti-GD1b, -GQ1b, and -GT1a ganglioside antibodies. A pathophysiological study in mice has shown that anti-GD1b antibodies, in comparison with anti-GM1/GD1a antibodies, preferentially target nodal axolemma in sensory nerves, leading to nodal disruption (63). An in vitro study on myelinating sensory neuron cultures has demonstrated both complement-dependent demyelination and complement-independent dysmyelination on exposure to anti-GD1b IgM antibody, indicating there may be multiple pathways mediating nerve injury (08).

Although the phenotype described here is distinctive, many cases of chronic sensory ataxic neuropathy do not have antidisialosyl antibodies. These cases, therefore, presumably have a different etiology that may be toxic, degenerative, genetic, or autoimmune. In a series of 17 patients with chronic idiopathic sensory ataxic neuropathy, only 3 of 17 patients had antidisialosyl antibodies (24). In the control group of 93 cases in which the etiology of the sensory ataxic neuropathy was known, no cases had antidisialosyl antibodies. Normal human sera do not contain these antibodies, indicating a high specificity for this distinctive syndrome and a likely causal relationship. In another report of two cases of chronic ataxic neuropathy, one case had antidisialosyl antibodies, whereas the other had anti-GD1a antibodies; the latter was more typically associated with pure motor syndromes (67). This curious case underlies some of the etiologic complexities that remain unresolved in this clinical area.

The antidisialosyl antibodies found in these disorders may arise through cross-reactivity with bacterial lipopolysaccharides, for example as carried on certain serostrains of Campylobacter jejuni. This molecular mimicry model has been substantiated for the anti-GQ1b antibodies that arise in Miller-Fisher syndrome and some of the anti-GQ1b antibodies found in Miller-Fisher syndrome also react with GD1b. Similar experiments have been conducted with antidisialosyl paraproteins and Campylobacter jejuni lipopolysaccharides that support this view (29). Exactly how these B lymphocyte antibody responses make the transition from acute phase immune responses to chronically stable, regulated clones of paraprotein-secreting B cells is unknown.

Detailed postmortem pathological studies on this syndrome are sparse. In one case report, an autopsy showed severe dorsal column atrophy, dorsal root ganglionopathy, and infiltration of clonal B-lymphocytes within the endoneurium, perineurium, and leptomeninges of peripheral nerve (46). It is curious that sural nerve biopsies from these patients have not shown any IgM deposition (unlike the IgM deposition seen in the anti-MAG paraproteinemic neuropathy), suggesting that the pathophysiology may be complex.

Differential diagnosis

Confusing conditions

A clinically similar pattern of sensory neuropathy and ataxia can be seen in a number of other conditions, including sensory variant chronic inflammatory demyelinating neuropathy and chronic immune sensory polyradiculopathy (59), paraneoplastic neuropathy, Sjogren syndrome (10; 53; 49; 76; 59). Furthermore, drug-induced and toxic neuropathies associated with semisynthetic penicillins (60) or neuropathies caused by pyridoxine overuse, cisplatinum, paclitaxel, methyl mercury, or thalidomide, vitamin deficiency syndromes (B12, B6, or E), neuropathies associated with HIV and human T cell lymphotrophic virus, and hereditary conditions including hereditary sensory and autonomic neuropathies, Friedreich ataxia, olivopontocerebellar atrophy, sensory ataxic neuropathy dysarthria with ophthalmoparesis (19), and abetalipoproteinemia may have a similar presentation (19). However, as explained above, the key feature is the presence of anti-GD1b antibody, which is an available commercial test that should be performed to confirm the diagnosis of CANDA or CANOMAD in the proper clinical scenario (74; 06; 14).

Associated or underlying disorders

As clear in the acronym CANOMAD, paraproteinemia is common in this syndrome, and monoclonal gammopathy is usually present in about 65% to 100% of patients, with essentially an equal distribution of Kappa and Lambda light chains. In some cases, Kappa and Lambda light chains may co-exist (71; 06; 14; 51). Of note, paraproteinemia may not be apparent at the time of initial presentation and can develop later in the disease process (46).

Hematological malignancies can co-exist and Waldenström macroglobulinemia has been reported in about 3.6% to 20% of patients from larger studies (40; 51). Different types of lymphoma, including diffuse large B cell lymphoma and other subtypes of B cel lymphoma, marginal zone lymphoma, mantle cell lymphoma, and chronic myeloid cell lymphoma, have been reported in some patients (35; 33; 40; 51).

Diagnostic workup

	• Blood work for paraproteinemia
	• Ganglioside antibodies
	• Cold agglutinins
	• Electrodiagnostic studies

As for any other neuropathy, basic workup to assess treatable causes of neuropathy per the American Academy of Neurology guideline is recommended, and assessment should include evaluation for vitamin deficiencies, toxic causes, and hereditary and infectious workup as applicable.

The diagnostic workup for the acute presentation of IgG anti-GD1b-mediated neuropathy should be similar to that for Guillain-Barré syndrome. Based on the current practice, electrodiagnostic studies, along with CSF analysis with or without spinal and nerve root imaging, are recommended. Given the uncertain evidence of whether these ganglioside antibodies may change management, routine testing for anti-ganglioside antibodies is not evidence-based.

For IgM anti-GD1b antibody-mediated CANDA/ or CANOMAD, strong clinical suspicion is required, particularly if there is cranial nerve involvement. Blood work to assess paraproteinemia and cold agglutinin can be helpful. However, cold agglutinins are not always present, and wide variations exist in terms of the presence of cold agglutinins (0% to 50%) (71; 40; 51).

Electrodiagnostic studies can help to assess the severity and characterize the pattern of neuropathy and can serve as a baseline but may not have specific diagnostic value. Both sensory and motor nerves can be involved. Two large studies from Europe reported about 60% of the cases with demyelinating neuropathy (40; 51), but others have reported both axonal and demyelinating patterns, and sometimes a mixed pattern (71; 14). Motor conduction block in the absence of anti-GM1 antibody has also been reported (35; 43; 27).

Cerebrospinal fluid analysis may show albumin cytological dissociation in some cases and can be helpful to rule out underlying infectious, inflammatory, or other etiologies. Occasional mild elevation of lymphocytes has been observed (71; 14; 40; 51). Similar to CSF studies, nerve biopsies do not have any specific diagnostic values and are not routinely recommended. However, nerve biopsy may be indicated in special circumstances, including rapid progression or suspicion for other etiologies. Reported findings include demyelination, endoneural fibrosis, and IgM deposits (71; 14; 40; 51). Inflammatory infiltrates are usually absent, but rare nonspecific epineurial lymphocytic infiltration can be observed (40).

When a central nervous system lesion is suspected, a CT or MRI of the brain should be performed. MRI brain is usually normal, but in some cases, central demyelination has been reported (71; 51). For patients with myelopathic signs, the spinal cord, including the region of the foramen magnum, should be investigated by myelography or MRI. Furthermore, MRI can show nerve root enhancement and hypertrophy, particularly of lumbosacral and brachial plexus (51). Neuromuscular ultrasound has shown regional nerve enlargement consistent with acquired demyelination in some cases (14).

Management

	• About 50% of patients are responsive to immunoglobulin.
	• B cell depletion therapy with rituximab can be beneficial.

No randomized clinical trials of treatment have been performed. Conventional immunomodulatory therapy with corticosteroid, plasma exchange, and intravenous immunoglobulin has been used with symptomatic benefit. Even in the absence of systematic studies, corticosteroids appear to be less effective without long-term lasting benefits, and disease progression is common (40). However, there can be reporting bias, and comparative studies are required (51).

More recent reports used immunoglobulin more frequently, and often successfully (33; 37; 52). In about 50% to 60% of cases, IVIg showed partial response and often prevented relapse (14; 40; 51). At present, it remains unclear if IVIg is particularly useful in patients with demyelinating features in electrodiagnostic studies.

However, in some cases there was disease relapse and progression despite immunoglobulin therapy, and B cell depletion therapy with rituximab has been successfully employed with long-lasting benefits (12; 42; 14; 40; 51). In a large study with a French cohort, rituximab either alone or in combination with other immunomodulatory agents showed positive response in 22 of 26 patients (40). Another study reported complete response in 50% of patients treated with rituximab (51). Similarly, rituximab successfully halted disease progression over 2 years in eight of nine patients from a United States cohort (14).

Other immunomodulatory and immunomodulatory therapies, including azathioprine, mycophenolate mofetil, chlorambucil, and intravenous cyclophosphamide have been used intermittently, but there is no definitive pattern in terms of treatment response (14; 40; 51).

In the presence of an IgM paraprotein, care should be taken to fully characterize any underlying hematological abnormality; in some cases, underlying Waldenström macroglobulinemia or different types of lymphoma have been identified, which requires specific treatment (58).

Treatment should always be offered with caution, and the risk-benefit analysis should be explained to the patient, particularly when using cytotoxic therapies or B cell depletion therapies. Pre-infusion tests for certain viral organisms and their prompt treatment are a helpful approach to prevent or limit flare-up of underlying infections. Vigilance for the emergence of infections, including opportunistic infections, is recommended when using immunosuppressive agents. Another point of caution is that the temperature of replacement fluids during plasma exchange, or during other intravenous fluid use, should be carefully controlled in patients with cold agglutinins to avoid intravascular agglutination.

References

01: Afrantou T, Kimiskidis V, Lagoudaki R, et al. Unusual phenotype of acute motor sensory axonal neuropathy with ophthalmoplegia, and anti-GD1a, -GD1b and -GM1 antibodies. Clin Exp Neuroimmunol 2022;13(4):267-71.
02: Arai M, Yoshino H, Kusano Y, Yasaki Y, Ohnishi Y, Miyatake T. Ataxic polyneuropathy and anti-Pr2 IgMk M proteinaemia. J Neurol 1992;239:147-51. PMID 1573418
03: Araki T, Kusunoki S, Arai Y, Terashi A. [Guillain-Barré syndrome with cerebellar symptoms and elevated serum anti-GD1b IgG antibody]. [Japanese] Rinsho Shinkeigaku 1999;39(5):527-30. PMID 10424143
04: Bhagat R, Brown M. Facial diplegia with preserved reflexes: an unusual case of anti-GD1b antibody associated Guillain-Barré syndrome. Innov Clin Neurosci 2021;18(7-9):18-20. PMID 34980989
05: Braun PE, Frail DE, Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 1982;39(5):1261-5. PMID 6181197
06: Caudie C, Vial C, Petiot P, Bouhour F. [Serum antibody profiles against gangliosides and sulfatide in peripheral neuropathies: evaluation of a new immunoassay] [Article in French]. Ann Biol Clin (Paris) 2010;68(6):675-80. PMID 21159581
07: Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9. PMID 1514781
08: Clark AJ, Kaller MS, Galino J, Willison HJ, Rinaldi S, Bennett DLH. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain 2017;140(4):898-913. PMID 28334857
09: Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol 2020;17(4):313-22. PMID 32152553
10: Dalakas MC, Quarles RH. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens. Ann Neurol 1996;39:419-22. PMID 8619518
11: Daune GC, Farrer RG, Dalakas MC, Quarles RH. Sensory neuropathy with monoclonal immunoglobulin M to GD1b ganglioside. Ann Neurol 1992;31(6):683-5. PMID 1381168
12: Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C. Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol 2010;257(4):655-7. PMID 19960199
13: Fujiwara S, Manabe Y, Nakano Y, Omote Y, Narai H, Abe K. A case of Miller-Fisher syndrome with syndrome of inappropriate secretion of antidiuretic hormone. Case Rep Neurol 2021;13(2):380-3. PMID 34248573
14: Garcia-Santibanez R, Zaidman CM, Sommerville RB, et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol 2018;265(6):1402-9. PMID 29633012
15: Glavey SV, Leung N. Monoclonal gammopathy: the good, the bad and the ugly. Blood Rev 2016;30(3):223-31. PMID 26732417
16: Guilmot A, Maldonado Slootjes S, Bissay V, Dubuisson N, de Broglie C, Gille M. SARS-CoV-2-associated Guillain-Barré syndrome in four patients: what do we know about pathophysiology? Acta Neurol Belg 2022;122(3):703-7. PMID 34476752
17: Guilmot A, Maldonado Slootjes S, Sellimi A, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol 2021;268(3):751-7. PMID 32734353
18: Gutierrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020;95(5):e601-5. PMID 32303650
19: Hanisch F, Kornhuber M, Alston CL, Taylor RW, Deschauer M, Zierz S. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry 2015;86(6):630-4. PMID 25143630
20: Herron B, Willison HJ, Veitch J, Roelcke D, Illis LS, Boulton FE. Monoclonal IgM cold agglutinins with anti-Pr1d specificity in a patient with peripheral neuropathy. Vox Sanguinis 1994;67:58-63. PMID 7975454
21: Hitoshi S, Kusunoki S, Chiba A, et al. Cerebellar-ataxia and polyneuropathy in a patient with Igm M-protein specific to the Gal(beta-1-3)GalNAc epitope. J Neurol Sci 1994;126:219-24. PMID 7531761
22: Ichikawa H, Susuki K, Yuki N, Kawamura M. [Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody]. [Japanese] Rinsho Shinkeigaku 2001;41(8):523-5. PMID 11889840
23: Ikuta N, Koga M, Ogasawara J, Morimatsu M, Yuki N. [Anti-GD1b IgG antibody-related Guillain-Barré syndrome initially mimicking brainstem infarction]. [Japanese] Rinsho Shinkeigaku 2001;41(2-3):132-5. PMID 11481856
24: Illa I, Rojas R, Gallardo E, Serrano C, Graus F. Chronic idiopathic sensory ataxic neuropathy: immunological aspects of a series of 17 patients. Rev Neurol (Paris) 2001;157:517-22. PMID 11438771
25: Ilyas AA, Cook SD, Dalakas MC, Mithen FA. Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide. J Neuroimmunol 1992;37:85-92. PMID 1372333
26: Ilyas AA, Quarles RH, Dalakas MC, Fishman PH, Brady RO. Monoclonal IgM in a patient with paraproteineamic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985;18:655-9. PMID 2417543
27: Iorio R, Capone F, Iannaccone E, et al. SIADH in a patient with sensory ataxic neuropathy with anti-disialosyl antibodies (CANOMAD). J Neurol 2009;256(7):1177-9. PMID 19252770
28: Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82:294-9. PMID 21252265
29: Jacobs BC, O'Hanlon G, Breedland EG, Veitch J, van Doorn PA, Willison HJ. Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. J Neuroimmunol 1997;80:23-30. PMID 9413256
30: Johnson K, Malkan A, Shaffi M. Facial involuntary movements and respiratory failure in CANOMAD, responsive to IVIG therapy. Case Rep Med 2015;2015:170543. PMID 26697071
31: Kaida K, Kamakura K, Ogawa G, et al. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome. Neurology 2008;71(3):196-201. PMID 18625966
32: Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 2004;56:567-71. PMID 15389898
33: Kam C, Balaratnam MS, Purves A, et al. Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve 2011;44(5):829-33. PMID 22006700
34: Kim S, Bae J, Park GY, Im S. Implications of anti-ganglioside antibodies in isolated dysphagia following COVID-19 infection: case series. Brain Behav 2024;14(5):e3514. PMID 38698593
35: Kobayashi M, Kato K, Funakoshi K, Watanabe S, Toyoshima I. Neuropathology of paraneoplastic neuropathy with anti-disialosyl antibody. Muscle Nerve 2005;32(2):216-22. PMID 15937876
36: Korona A, Maritsi D, Markante A, Stamati A, Mouskou S, Vartzelis G. Eyes wide open-an atypical presentation of Miller Fisher syndrome (MFS): case report. Egypt J Neurol Psychiatr Neurosurg 2022;58(1):14.
37: Krenn M, Keir G, Wieshmann UC. CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg). BMJ Case Rep 2014;2014. PMID 24722712
38: Kusunoki S, Mashiko H, Mochizuki N, et al. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve 1997;20:840-5. PMID 9179156
39: Kusunoki S, Shimizu T, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996;39:424-30. PMID 8619520
40: Le Cann M, Bouhour F, Viala K, et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood 2020;136(21):2428-36.** PMID 32959046
41: Liu JX, Willison HJ, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50(7):3226-32. PMID 19255160
42: Loscher WN, Woertz A, Wallnöfer M, Wanschitz JV, Luef G. Successful treatment of CANOMAD with IVIg and rituximab. J Neurol 2013;260(4):1168-70. PMID 23400502
43: Marfia GA, Pachatz C, Terracciano C, et al. Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b. Neurol Sci 2005;26(5):355-7. PMID 16388373
44: Masuccio FG, Barra M, Claudio G, Claudio S. A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection. J Neurol 2021;268(7):2327-30. PMID 32940797
45: Matsuzono K, Ozawa T, Yoshikawa K, Kusunoki S, Fujimoto S. A case report of Fisher syndrome with the detection of anti-GM3 and anti-GD1b IgG antibodies. Neurol Sci 2019;40(4):891-3. PMID 30471020
46: McKelvie PA, Gates PC, Day T. Canomad: report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade. Muscle Nerve 2013;48(4):599-603. PMID 23649749
47: Obi T, Kusunoki S, Takatsu M, Mizoguchi K, Nishimura Y. IgM M-protein in a patient with sensory-dominant neuropathy binds preferentially to polysialogangliosides. Acta Neurol Scand 1992;86:215-8. PMID 1384262
48: Oka N, Kusaka H, Kusunoki S, et al. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 1996;19:528-30. PMID 8622736
49: O'Leary C, Willison HJ. Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol 1997;0:366-70. PMID 9330880
50: Pan CL, Yuki N, Koga M, Chiang MC, Hsieh ST. Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. Neurology 2001 9;57(7):1316-8. PMID 11591857
51: Peillet C, Adams D, Attarian S, et al. Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study. Eur J Neurol 2022;29(12):3547-55.** PMID 35969369
52: Ponsford S, Willison HJ, Veitch J, Morris R, Thomas PK. Long term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated with benign monoclonal gammopathy. Muscle Nerve 2000;23:164-74. PMID 10639606
53: Pourmand R, Maybury BG. AAEM case report #31: paraneoplastic sensory neuropathy. Muscle Nerve 1996;19:1517-22. PMID 8941264
54: Quarles RH. The spectrum and pathogenesis of antibody-mediated neuropathies. Neuroscientist 1997;3:195-204.
55: Roberts M, Willison HJ, Vincent A, Newsom-Davis J. Serum factor in the Miller Fisher variant of Guillain-Barre syndrome blocks neurotransmitter release. Lancet 1994;343:454-5. PMID 7905957
56: Rojas-Garcia R, Gallardo E, Povedano M, et al. Antibodies against disialosyl and terminal NeuNAc(alpha2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. J Neurol 2008;255(5):764-6. PMID 18344054
57: Sanvito L, Rajabally YA. Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve 2011;44:451-5. PMID 21996808
58: Shihashi G, Yagi T, Suzuki S, et al. Immune-mediated neuropathy with anti-disialosyl IgM antibodies in diffuse large B-cell lymphoma: a case report and literature review. Intern Med 2015;54(13):1647-51. PMID 26134199
59: Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004;63(9):1662-9. PMID 15534252
60: Sterman AB, Schaumburg HH, Asbury AK. The acute sensory neuronopathy syndrome: a distinct clinical entity. Ann Neurol 1980;7(4):354-8. PMID 6246836
61: Stork AC, van der Pol WL, Franssen H, Jacobs BC, Notermans NC. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol 2014;261(7):1398-404. PMID 24781837
62: Susuki K, Yuki N, Hirata K. Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol 2001;112:181-7. PMID 11108947
63: Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012;233:534-42. PMID 22178332
64: Taams NE, Notermans NC, Fokkink WR, et al. Clinical relevance of serum antibodies to GD1b in immune‐mediated neuropathies. J Periph Nerv Syst 2018;23(4):227-34. PMID 30101437
65: Takada K, Shimizu J, Kusunoki S. Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol 2008:209(1);279-83. PMID 17964572
66: Tan CY, Razali SN, Goh KJ, Shahrizaila N. Determining the utility of the Guillain-Barré syndrome classification criteria. J Clin Neurol 2021;17(2):273-82. PMID 33835749
67: Villa AM, Lopez PH, Sevlever G, Nores GA, Sica RE. Antiganglioside antibodies in serum of patients with chronic sensory ataxic neuropathy. Medicina (B Aires) 2002;62:237-40. PMID 12150006
68: Wicklein EM, Pfeiffer G, Yuki N, Hartard C, Kunze K. Prominent sensory ataxia in Guillain-Barre syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997;151:227-9. PMID 9349681
69: Willison HJ, Almemar A, Veitch J, Thrush D. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology 1994;44(12):2395-7. PMID 7991134
70: Willison HJ, O'Hanlon GM, Paterson G, et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy gene chain, V1-18. J Clinl Invest 1996;97:1155-64. PMID 8635426
71: Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124:1968-77. PMID 11571215
72: Willison HJ, Paterson G, Veitch J, Inglis G, Barnett SC. Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J Neurol Neurosurg Psychiatry 1993;56:1178-84. PMID 7693874
73: Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994;50:159-65. PMID 8120137
74: Willison HJ, Veitch J, Swan AV, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999;6(1):71-7. PMID 10209353
75: Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591-625. PMID 12429589
76: Wokke JH, Van Dijk GW. Sensory neuropathies including painful and toxic neuropathies. J Neurol 1997;244:209-21. PMID 9112589
77: Younes-Chennoufi AB, Leger JM, Hauw JJ, et al. Ganglioside GD1b is the target antigen for a biclonal IgM in a case of sensory-motor axonal polyneuropathy - involvement of N-Acetylneuraminic acid in the epitope. Ann Neurol 1992;32:18-23. PMID 1379422
78: Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med 2012;366(24):2294-304. PMID 22694000
79: Yuki N, Hirata K. Postinfection sensory neuropathy associated with IgG anti-GD1b antibody. Ann Neurol 1998;43:685-7. PMID 9585370
80: Yuki N, Miyatani N, Sato S, et al. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAcb1-4(Gal3-2aNeuAc8-2aNeuAc)b1 configuration. Neurol 1992;42(3 Pt 1):686-9. PMID 1549241
81: Yuki N, Susuki K, Hirata K. Ataxic form of Guillain-Barr syndrome associated with anti-GD1b IgG antibody. J Neurol Neurosurg Psychiatry 2000;69(1):136-7. PMID 10864627
82: Yuki N, Uncini A. Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve 2014;49(5):629-35. PMID 24477718

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Mazen M Dimachkie MD

Dr. Dimachkie, Director of the Neuromuscular Disease Division and Executive Vice Chairman for Research Programs, Department of Neurology, The University of Kansas Medical Center received consultant honorariums from Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/LabCorp, CSL Behring, Dianthus, EMD Serono/Merck, Horizon, Ig Society Inc, Ipsen, Janssen, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Shire/Takeda, Treat NMD/TACT, and Valenza Bio. Dr. Dimachikie also received research grants from Alexion/Astra Zaneca, Amicus, Astellas, Catalyst, CSL Behring, EMD Serono/Merck, Genentech, Grifols, GSK, Horizon, Janssen, Mitsubishi Tanabe Pharma, MT Pharma, Novartis, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire/Takeda, and TMA.
See Profile
Bhaskar Roy MBBS MHS

Dr. Roy of Yale Medicine received a consultation fee from Argenx and owns stock in Cabaletta Bio.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Hugh J Willison MD

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Neuropathy associated with anti-GD1b ganglioside antibodies

Associated Disorders

Anti-disialosyl or anti-B series ganglioside antibodies
CANOMAD (chronic ataxic neuropathy with ophthalmoplegia, M-protein, agglutination, and disialosyl antibodies)
Cold agglutinin disease
IgM paraproteinemia
Peripheral neuropathy with anti-GD1
- Sensory ataxic neuropathy
- Sensory neuropathy

Differential Diagnosis

other autoimmune conditions
sensory variants of chronic inflammatory demyelinating neuropathy
paraproteinemic neuropathies with other sero-specificities
paraneoplastic neuropathies
neuropathies associated with Sjögren syndrome/Sicca complex and primary biliary cirrhosis
- neuropathies associated with HIV and human T cell lymphotrophic virus
- drug-induced and toxic neuropathies
- vitamins B12, B6, and E deficiency syndromes
- hereditary sensory and autonomic neuropathies
- Friedreich ataxia
- olivopontocerebellar atrophy
- abetalipoproteinemia
- chronic idiopathic ataxic neuropathy
- idiopathic sensory neuropathy

Neuropathy associated with anti-GD1b ganglioside antibodies

Neuropathy associated with anti-GD1b ganglioside antibodies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-IgLON5 disease

Anti-LGI1 encephalitis

Giant cell arteritis

Myositis and cancer

Leukodystrophies

Neurolymphomatosis

Anti-NMDA receptor encephalitis

Spinal accessory neuropathy

Neuropathy associated with anti-GD1b ganglioside antibodies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-IgLON5 disease

Anti-LGI1 encephalitis

Giant cell arteritis

Myositis and cancer

Leukodystrophies

Neurolymphomatosis

Anti-NMDA receptor encephalitis

Spinal accessory neuropathy

This is an article preview.
Start a Free Account
to access the full version.